Intravitreal Injection of Lucentis (Ranibizumab) after Pars Plana Vitrectomy and Subretinal Application of Recombinant Tissue Plasminogen Activator (rtPA) in Patients with Acute Submacular Hemorrhage as Complication of Exsudative Age-related Macular Degeneration (AMD).[ Intravitreale Lucentisinjektion (Ranibizumab) nach pars plana Vitrektomie und subretinaler Applikation von recombinant tissue plasminogen activator (rtPA) bei akuter submakulärer Blutung als Komplikation der exsudativen altersabhängigen Makuladegeneration (AMD).]

Trial Profile

Intravitreal Injection of Lucentis (Ranibizumab) after Pars Plana Vitrectomy and Subretinal Application of Recombinant Tissue Plasminogen Activator (rtPA) in Patients with Acute Submacular Hemorrhage as Complication of Exsudative Age-related Macular Degeneration (AMD).[ Intravitreale Lucentisinjektion (Ranibizumab) nach pars plana Vitrektomie und subretinaler Applikation von recombinant tissue plasminogen activator (rtPA) bei akuter submakulärer Blutung als Komplikation der exsudativen altersabhängigen Makuladegeneration (AMD).]

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Mar 2016

At a glance

  • Drugs Ranibizumab (Primary) ; Alteplase
  • Indications Ocular haemorrhage; Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms SubMacHem
  • Sponsors Novartis
  • Most Recent Events

    • 02 Mar 2016 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
    • 02 Mar 2016 Last checked against the European Clinical Trials Database record.
    • 12 Feb 2014 New source identified and integrated.German Clinical Trials Register (DRKS)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top